Zasocitinib

N/A

Report date: 2026/05/12 20:00:17
NME

Base Information

Drug NameZasocitinib
Drug Alias NameNDI-034858TAK-279
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase 2 inhibitorsProtein allosteric inhibitors
TargetsTyrosine-protein kinase 2
Therapy Area/IndicationsPlaque psoriasisGeneralised pustular psoriasisErythrodermic psoriasis +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[35] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesNimbus Therapeutics LLC
China Registration ClassN/A

Develop Information

Active CompaniesTakeda (China) International Trading Co LtdSerán BioScience LLCCelgene Corp +[6] 
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisGeneralised pustular psoriasisErythrodermic psoriasis +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A